OBJECTIVE: To determine the incidence of cerebral microbleeds (CMBs) and the association of amyloid PET burden with incident CMBs. METHODS: A total of 651 participants, age ≥50 years (55% male), underwent 3T MRI scans with ≥2 separate T2*-weighted gradient recalled echo sequences from October 2011 to August 2017. Eighty-seven percent underwent 11C Pittsburgh compound B (PiB) PET scans. Age-specific CMB incidence rates were calculated by using the piecewise exponential model. Using structural equation models (SEMs), we assessed the effect of amyloid load and baseline CMBs on future CMBs after considering the direct and indirect age, sex, vascular risk factors, and APOE effects. RESULTS: Participants' mean age (SD) was 69.8 (10.0) years at baseline MRI, and 111 participants (17%) had ≥1 baseline CMB. The mean (SD) of the time interval between scans was 2.7 (1.0) years. The overall population incidence rate for CMBs was 3.6/100 person-years and increased with age: from 1.5/100 new CMBs at age 50 to 11.6/100 person-years at age 90. Using the piecewise exponential model regression, the incidence rates increased with age and the presence of baseline CMBs. The SEMs showed that (1) increasing age at MRI or carrying an APOE4 allele was associated with more amyloid at baseline, and higher amyloid, particularly occipital amyloid load, in turn increased the risk of a new lobar CMB; and (2) the presence of CMBs at baseline increased the risk of a lobar CMB and had a larger effect size than amyloid load. CONCLUSIONS: Age and APOE4 carrier status act through amyloid load to increase the risk of subsequent lobar CMBs, but the presence of baseline CMBs is the most important risk factor for future CMBs.
OBJECTIVE: To determine the incidence of cerebral microbleeds (CMBs) and the association of amyloid PET burden with incident CMBs. METHODS: A total of 651 participants, age ≥50 years (55% male), underwent 3T MRI scans with ≥2 separate T2*-weighted gradient recalled echo sequences from October 2011 to August 2017. Eighty-seven percent underwent 11C Pittsburgh compound B (PiB) PET scans. Age-specific CMB incidence rates were calculated by using the piecewise exponential model. Using structural equation models (SEMs), we assessed the effect of amyloid load and baseline CMBs on future CMBs after considering the direct and indirect age, sex, vascular risk factors, and APOE effects. RESULTS:Participants' mean age (SD) was 69.8 (10.0) years at baseline MRI, and 111 participants (17%) had ≥1 baseline CMB. The mean (SD) of the time interval between scans was 2.7 (1.0) years. The overall population incidence rate for CMBs was 3.6/100 person-years and increased with age: from 1.5/100 new CMBs at age 50 to 11.6/100 person-years at age 90. Using the piecewise exponential model regression, the incidence rates increased with age and the presence of baseline CMBs. The SEMs showed that (1) increasing age at MRI or carrying an APOE4 allele was associated with more amyloid at baseline, and higher amyloid, particularly occipital amyloid load, in turn increased the risk of a new lobar CMB; and (2) the presence of CMBs at baseline increased the risk of a lobar CMB and had a larger effect size than amyloid load. CONCLUSIONS: Age and APOE4 carrier status act through amyloid load to increase the risk of subsequent lobar CMBs, but the presence of baseline CMBs is the most important risk factor for future CMBs.
Authors: Keith A Johnson; Matt Gregas; John A Becker; Catherine Kinnecom; David H Salat; Erin K Moran; Erin E Smith; Jonathan Rosand; Dorene M Rentz; William E Klunk; Chester A Mathis; Julie C Price; Steven T Dekosky; Alan J Fischman; Steven M Greenberg Journal: Ann Neurol Date: 2007-09 Impact factor: 10.422
Authors: José Rafael Romero; Sarah R Preis; Alexa Beiser; Charles DeCarli; Anand Viswanathan; Sergi Martinez-Ramirez; Carlos S Kase; Philip A Wolf; Sudha Seshadri Journal: Stroke Date: 2014-04-08 Impact factor: 7.914
Authors: Mariëlle M F Poels; M Arfan Ikram; Aad van der Lugt; Albert Hofman; Gabriel P Krestin; Monique M B Breteler; Meike W Vernooij Journal: Stroke Date: 2011-02-09 Impact factor: 7.914
Authors: Jae-Hyun Park; Sang Won Seo; Changsoo Kim; Geon Ha Kim; Hyun Jin Noh; Sung Tae Kim; Ki-Chang Kwak; Uicheul Yoon; Jong Min Lee; Jong Weon Lee; Ji Soo Shin; Chi Hun Kim; Young Noh; Hanna Cho; Hee Jin Kim; Cindy W Yoon; Seung Jun Oh; Jae Seung Kim; Yearn Seong Choe; Kyung-Han Lee; Jae-Hong Lee; Michael Ewers; Michael W Weiner; David J Werring; Duk L Na Journal: Ann Neurol Date: 2013-03-12 Impact factor: 10.422
Authors: Chengxuan Qiu; Mary Frances Cotch; Sigurdur Sigurdsson; Melissa Garcia; Ronald Klein; Fridbert Jonasson; Barbara E K Klein; Gudny Eiriksdottir; Tamara B Harris; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer Journal: Diabetes Date: 2008-03-10 Impact factor: 9.461
Authors: M W Vernooij; A van der Lugt; M A Ikram; P A Wielopolski; W J Niessen; A Hofman; G P Krestin; M M B Breteler Journal: Neurology Date: 2008-04-01 Impact factor: 9.910
Authors: Jonathan Graff-Radford; Jeannette Simino; Kejal Kantarci; Thomas H Mosley; Michael E Griswold; B Gwen Windham; A Richey Sharrett; Marilyn S Albert; Rebecca F Gottesman; Clifford R Jack; Prashanthi Vemuri; David S Knopman Journal: Stroke Date: 2017-10-10 Impact factor: 7.914
Authors: Prashanthi Vemuri; Jeffrey L Gunter; Matthew L Senjem; Jennifer L Whitwell; Kejal Kantarci; David S Knopman; Bradley F Boeve; Ronald C Petersen; Clifford R Jack Journal: Neuroimage Date: 2007-10-22 Impact factor: 6.556
Authors: M Edip Gurol; J Alex Becker; Panagiotis Fotiadis; Grace Riley; Kristin Schwab; Keith A Johnson; Steven M Greenberg Journal: Neurology Date: 2016-09-07 Impact factor: 9.910
Authors: Jonathan Graff-Radford; Timothy G Lesnick; Michelle M Mielke; Eleni Constantopoulos; Alejandro A Rabinstein; Scott A Przybelski; Prashanthi Vemuri; Hugo Botha; David T Jones; Vijay K Ramanan; Ronald C Petersen; David S Knopman; Bradley F Boeve; Melissa E Murray; Dennis W Dickson; Clifford R Jack; Kejal Kantarci; R Ross Reichard Journal: J Alzheimers Dis Date: 2021 Impact factor: 4.472
Authors: M Buciuc; J R Duffy; M M Machulda; A J Spychalla; J L Gunter; C R Jack; C Giannini; A Raghunathan; D W Dickson; K A Josephs; J L Whitwell Journal: Eur J Neurol Date: 2020-11-12 Impact factor: 6.089
Authors: L Grangeon; G Quesney; X Ayrignac; D Wallon; M Verdalle-Cazes; S Coulette; D Renard; A Wacongne; T Allou; N Olivier; Y Boukriche; G Blanchet-Fourcade; P Labauge; C Arquizan; S Canaple; O Godefroy; O Martinaud; P Verdure; M Quillard-Muraine; J Pariente; E Magnin; G Nicolas; C Charbonnier; D Maltête; M Formaglio; N Raposo Journal: J Neurol Date: 2022-06-26 Impact factor: 6.682
Authors: Michelle G Jansen; Ludovica Griffanti; Clare E Mackay; Melis Anatürk; Luca Melazzini; Ann-Marie G de Lange; Nicola Filippini; Enikő Zsoldos; Kim Wiegertjes; Frank-Erik de Leeuw; Archana Singh-Manoux; Mika Kivimäki; Klaus P Ebmeier; Sana Suri Journal: J Cereb Blood Flow Metab Date: 2021-10-05 Impact factor: 6.960
Authors: Eseosa T Ighodaro; Jonathan Graff-Radford; Jeremy A Syrjanen; Hai H Bui; Ronald C Petersen; David S Knopman; Clifford R Jack; Samantha M Zuk; Prashanthi Vemuri; Michelle M Mielke Journal: Arterioscler Thromb Vasc Biol Date: 2020-09-03 Impact factor: 8.311
Authors: Stuart J McCarter; Timothy G Lesnick; Val Lowe; Michelle M Mielke; Eleni Constantopoulos; Alejandro A Rabinstein; Scott A Przybelski; Hugo Botha; David T Jones; Vijay K Ramanan; Clifford R Jack; Ronald C Petersen; David Knopman; Bradley F Boeve; Melissa E Murray; Dennis W Dickson; Prashanthi Vemuri; Kejal Kantarci; R Ross Reichard; Jonathan Graff-Radford Journal: Neurology Date: 2021-09-09 Impact factor: 9.910